- Home
- BGR vs CADL Comparison
BGR vs CADL Comparison
Compare BGR & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGR
- CADL
- Stock Information
- Founded
- BGR 2004
- CADL 1999
- Country
- BGR United States
- CADL United States
- Employees
- BGR N/A
- CADL N/A
- Industry
- BGR Trusts Except Educational Religious and Charitable
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- BGR Finance
- CADL Health Care
- Exchange
- BGR Nasdaq
- CADL Nasdaq
- Market Cap
- BGR 338.6M
- CADL 306.4M
- IPO Year
- BGR N/A
- CADL 2021
- Fundamental
- Price
- BGR $13.63
- CADL $5.31
- Analyst Decision
- BGR
- CADL Strong Buy
- Analyst Count
- BGR 0
- CADL 4
- Target Price
- BGR N/A
- CADL $21.00
- AVG Volume (30 Days)
- BGR 73.3K
- CADL 1.1M
- Earning Date
- BGR 01-01-0001
- CADL 03-13-2025
- Dividend Yield
- BGR 6.02%
- CADL N/A
- EPS Growth
- BGR N/A
- CADL N/A
- EPS
- BGR 0.69
- CADL N/A
- Revenue
- BGR N/A
- CADL N/A
- Revenue This Year
- BGR N/A
- CADL N/A
- Revenue Next Year
- BGR N/A
- CADL N/A
- P/E Ratio
- BGR $18.97
- CADL N/A
- Revenue Growth
- BGR N/A
- CADL N/A
- 52 Week Low
- BGR $11.38
- CADL $1.56
- 52 Week High
- BGR $13.37
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- BGR 60.66
- CADL 28.78
- Support Level
- BGR $13.40
- CADL $7.85
- Resistance Level
- BGR $13.77
- CADL $5.90
- Average True Range (ATR)
- BGR 0.19
- CADL 0.63
- MACD
- BGR 0.03
- CADL -0.35
- Stochastic Oscillator
- BGR 82.05
- CADL 4.80
About BGR BlackRock Energy and Resources Trust
BlackRock Energy & Resources Trust is a closed-end equity fund providing total return through a combination of current income, gains and capital appreciation by investing in equity securities and derivatives of energy and natural resources companies. The fund invests in various sectors such as information technology, financials, healthcare, consumer discretionary, industrial, energy, materials and utilities.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.